Sirios Capital Management L P Sells 1,269 Shares of Becton, Dickinson and Company (NYSE:BDX)

Sirios Capital Management L P lowered its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 2.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,947 shares of the medical instruments supplier's stock after selling 1,269 shares during the quarter. Becton, Dickinson and Company makes up approximately 1.7% of Sirios Capital Management L P's portfolio, making the stock its 20th biggest position. Sirios Capital Management L P's holdings in Becton, Dickinson and Company were worth $9,743,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of BDX. Brighton Jones LLC lifted its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after purchasing an additional 877 shares during the last quarter. E. Ohman J or Asset Management AB lifted its stake in shares of Becton, Dickinson and Company by 13.4% in the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier's stock valued at $39,951,000 after acquiring an additional 20,859 shares during the last quarter. Busey Bank boosted its holdings in Becton, Dickinson and Company by 3.8% during the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier's stock valued at $15,031,000 after acquiring an additional 2,399 shares during the period. Centre Asset Management LLC bought a new position in Becton, Dickinson and Company during the 4th quarter worth approximately $8,382,000. Finally, Nordea Investment Management AB increased its stake in Becton, Dickinson and Company by 31.0% in the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier's stock worth $647,082,000 after purchasing an additional 673,568 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. StockNews.com raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, April 2nd. Barclays decreased their price objective on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a research report on Monday, April 7th. Finally, Piper Sandler dropped their target price on shares of Becton, Dickinson and Company from $280.00 to $260.00 and set an "overweight" rating for the company in a report on Wednesday. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $272.86.

Becton, Dickinson and Company Stock Up 0.4 %

NYSE:BDX traded up $0.85 during mid-day trading on Friday, hitting $205.30. 1,690,556 shares of the company's stock were exchanged, compared to its average volume of 1,733,174. Becton, Dickinson and Company has a one year low of $193.03 and a one year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The company has a market cap of $58.95 billion, a PE ratio of 34.10, a P/E/G ratio of 1.63 and a beta of 0.35. The business has a fifty day moving average price of $218.51 and a 200 day moving average price of $227.33.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Monday, March 10th were paid a $1.04 dividend. The ex-dividend date was Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 2.03%. Becton, Dickinson and Company's dividend payout ratio is presently 69.10%.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase plan on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company's board of directors believes its shares are undervalued.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 700 shares of the business's stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the completion of the transaction, the director now owns 36,033 shares of the company's stock, valued at approximately $8,215,163.67. The trade was a 1.91 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 479 shares of the stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the transaction, the executive vice president now owns 4,887 shares in the company, valued at approximately $964,107.36. This trade represents a 8.93 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,578 shares of company stock worth $795,986. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.